Internal Reference Number: FOI_8388
Date Request Received: 17/01/2025 00:00:00
Date Request Replied To: 05/02/2025 00:00:00
This response was sent via: By Email
Request Summary: intra-vitreal injections or implants
Request Category: Researcher
Question Number 1: How many of the following intra-vitreal injections/implants has your trust administered in the four-month period from September to December 2024: • Aflibercept • Bevacizumab • Brolucizumab • Dexamethasone • Faricimab • Fluocinolone acetonide • Ranibizumab - Lucentis • Ranibizumab - Biosimilar (Ongavia, Ximluci, Byooviz, Rimmyrah) | |
Answer To Question 1: • Aflibercept 1069 • Bevacizumab 8 • Brolucizumab 0 • Dexamethasone 12 • Faricimab 929 • Fluocinolone acetonide 0 • Ranibizumab - Lucentis 5 • Ranibizumab - Biosimilar (Ongavia, Ximluci, Byooviz, Rimmyrah) 0 | |
Question Number 2: Please see attached | |
Answer To Question 2: Please see attached. To accompany this answer to question 2 please also see the documents listed below: ![]() | |
Please see Attachments: | |
To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.